Skip to main content
| News

Moderna driving forward production of vaccine from Basel

11.08.2020

Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of a vaccine.

Moderna is headquartered in Cambridge, Massachusetts in the USA. The biotech firm has now established a subsidiary in Basel, located close to Lonza, which is Moderna’s production partner. In establishing the new Moderna Switzerland GmbH, the company was “actively supported” by Basel Area Business & Innovation, as detailed by the investment and innovation promotion agency in a statement. The support ranged from answering questions related to setting up a company and work permits in view of the COVID-19 pandemic situation all the through to suggestions with regard to office space. The attractiveness of the biotech ecosystem in the Basel Area has been underlined following Moderna’s successful establishment of a new subsidiary in the region.

The new location will be managed by Nicolas Chornet, who has been appointed Senior Vice President International Manufacturing, Europe at Moderna. “Establishing a European presence for Moderna is key to delivering on our manufacturing commitments outside of the U.S., and an important aspect of our future growth plans”, explains Chornet, who previously spent ten years working for Novartis, in the press release.

The government has reached an agreement with Moderna for the delivery of 4.5 million doses of a coronavirus vaccine. Moderna’s development is focused on what is known as an mRNA vaccine. The mRNA is a type of messenger molecule that carries an instruction manual for the production of proteins and tells body cells how to produce a virus protein. As soon as the body starts to produce the protein, the immune system recognizes it as an antigen. After this, antibodies against the virus are produced, with the aim here being to prepare the body to fight the virus. A Phase 3 study focusing on this issue is currently being conducted in the USA.

“With Moderna’s vaccine candidate for COVID-19 now in Phase 3 clinical trials, we’re pleased to have Nicolas building our capabilities to deliver mRNA solutions to Europe and other countries outside the US, from Switzerland with our strategic partner Lonza”, comments Stéphane Bancel, CEO of Moderna, in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.